Who owns BCAX?
Institutional ownership of Bicara Therapeutics Inc. from Form 13F, Q2 2026
171 institutional managers reported holding Bicara Therapeutics Inc. (BCAX) in Form 13F filings for Q2 2026, with 69,783,679 shares worth $2.1B. The largest reported holder was Ra Capital Management, L.p. Managers that filed both quarters cut a net 1,332,780 shares (-2.0%). 36 opened new positions and 13 sold out.
- Funds holding
- 171
- Value held
- $2.1B
- New / sold out
- 36 / 13
- Net shares, same filers
- -2.0%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of BCAX
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Ra Capital Management, L.p. | $215M | 10.4% | 7,255,993 | Unchanged |
| T. Rowe Price Investment Management, Inc. | $188M | 9.1% | 6,338,487 | Trimmed |
| Siren, L.L.C. | $166M | 8.0% | 5,602,970 | Trimmed |
| Vestal Point Capital, LP | $156M | 7.5% | 5,250,000 | Trimmed |
| Deep Track Capital, LP | $122M | 5.9% | 4,100,000 | Added |
| BlackRock, Inc. | $114M | 5.5% | 3,848,090 | Added |
| Jupiter Topco LLC | $94.0M | 4.5% | 3,171,015 | First report |
| Red Tree Management, LLC | $93.9M | 4.5% | 3,163,517 | Trimmed |
| TPG GP A, LLC | $89.4M | 4.3% | 3,010,425 | Unchanged |
| Vanguard Capital Management LLC | $65.8M | 3.2% | 2,216,639 | Added |
| State Street Corp | $60.8M | 2.9% | 2,048,920 | Added |
| Franklin Resources Inc | $58.0M | 2.8% | 1,951,892 | Added |
| Price T Rowe Associates Inc | $56.5M | 2.7% | 1,904,248 | Added |
| FMR LLC | $56.2M | 2.7% | 1,893,070 | Trimmed |
| Omega Fund Management, LLC | $54.1M | 2.6% | 1,822,150 | Trimmed |
| Geode Capital Management, LLC | $34.5M | 1.7% | 1,162,635 | Added |
| JPMorgan Chase & Co | $29.8M | 1.5% | 1,015,965 | Added |
| Jones Hill Capital LP | $26.5M | 1.3% | 892,621 | Trimmed |
| Acorn Capital Advisors, LLC | $19.1M | 0.9% | 643,381 | Unchanged |
| Aisling Capital Management LP | $16.9M | 0.8% | 568,919 | Unchanged |
| Palo Alto Investors LP | $16.3M | 0.8% | 550,408 | Unchanged |
| Rock Springs Capital Management LP | $15.9M | 0.8% | 535,286 | Added |
| Goldman Sachs Group Inc | $15.5M | 0.7% | 520,567 | Trimmed |
| D. E. Shaw & Co., Inc. | $14.8M | 0.7% | 498,193 | Added |
| Dimensional Fund Advisors LP | $13.7M | 0.7% | 461,724 | Added |
Share of 13F holdings is each fund's shares as a share of the 69,783,679 BCAX shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- BlackRock, Inc. Added+$29.8M
- JPMorgan Chase & Co Added+$24.6M
- State Street Corp Added+$18.7M
- Price T Rowe Associates Inc Added+$15.7M
- Vanguard Capital Management LLC Added+$13.1M
- Dimensional Fund Advisors LP Added+$10.5M
- Geode Capital Management, LLC Added+$9.9M
- Franklin Resources Inc Added+$9.8M
- Ameriprise Financial Inc Added+$8.1M
- Walleye Capital LLC Added+$7.3M
Biggest sellers in Q2 2026
- Royalty Pharma Sub-Manager, LLC Sold out-$46.7M
- Citadel Advisors LLC Trimmed-$43.0M
- Atle Fund Management AB Trimmed-$30.4M
- FIL Ltd Trimmed-$18.3M
- Omega Fund Management, LLC Trimmed-$16.9M
- Orbimed Advisors LLC Trimmed-$14.1M
- Jones Hill Capital LP Trimmed-$10.9M
- T. Rowe Price Investment Management, Inc. Trimmed-$7.9M
- FMR LLC Trimmed-$6.2M
- Siren, L.L.C. Trimmed-$5.9M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $220M and sold $234M; 67 added and 38 trimmed.
Schedule 13D and 13G filings on BCAX
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-07-27BlackRock, Inc. SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
- 2026-05-15JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
- 2026-02-17T. Rowe Price Investment Management, Inc. SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
- 2026-02-12Deep Track Capital, LP SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
- 2025-07-17FMR LLC SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
- 2025-05-15Vestal Point Capital, LP SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
- 2025-03-03FMR LLC SCHEDULE 13G filed by Bicara Therapeutics Inc.Schedule 13G
Questions about BCAX ownership
- Who owns BCAX stock?
- 171 institutional investment managers reported BCAX positions in their Form 13F filings for Q2 2026, holding 69,783,679 shares worth $2.1B in total. Ra Capital Management, L.p. reported the largest position.
- Are funds buying or selling BCAX?
- In Q2 2026, 36 managers opened new BCAX positions, 67 added, 38 trimmed and 13 sold out. Managers that filed in both quarters sold a net 1,332,780 shares.
- How current is this BCAX institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to BCAX by CUSIP. Options are left out. BCAX news and filings · BCAX insider trades · Top funds